Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11560555 Engineered proteins

Patent 11560555 was granted and assigned to Scribe Therapeutics on January, 2023 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Applicant

Scribe Therapeutics

0

Current Assignee

Scribe Therapeutics

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Benjamin Oakes0

Maroof Adil0

Sarah Denny0

Sean Higgins0

Brett T. Staahl0

Hannah Spinner0

Isabel Colin0

Katherine Baney0

...

Date of Patent

January 24, 2023

0

Patent Application Number

175339970

Date Filed

November 23, 2021

0

Patent Citations

US Patent 10253365 Type V CRISPR/Cas effector proteins for cleaving ssDNAs and detecting target DNAs

US Patent 10570415 RNA-guided nucleic acid modifying enzymes and methods of use thereof

Patent Citations Received

US Patent 12084692 Guide scaffolds

0

US Patent 11976277 Particle delivery systems

0

Patent Primary Examiner

0

Provided herein are engineered proteins comprising a RuvC DNA cleavage domain comprising one or more amino acid modifications, and one or more improved characteristics, relative to a naturally occurring RuvC domain. Also provided are gene editing systems comprising engineered proteins, and methods for use thereof.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11560555 Engineered proteins

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.